A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types. The study, which is a Phase I/II treatment arm within the eSMART Trial, was carried out at the Cancer Research UK Clinical Trials Unit (CRCTU), recruited 70 patients, and of those 66 were treated across four countries (the UK, France, the Netherlands and Spain). All these patients had solid tumors, 36 had Ewing Sarcoma and 34 had various other tumor types, mainly types of sarcoma and central nervous system tumors.
Continue Reading this article here
